Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.52 |
| ▸ | ACE | P12821 | 3/20 | 0.52 |
| ▸ | GRN | P28799 | 5/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.46 |
| ▸ | SHMT1 | P34896 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870264 | 1.00 | ACE2 (0.52) | ACE2ACEGRNSORT1SHMT1 | |
| SCHEMBL5870231 | 0.93 | ACE2 (0.53) | ACE2ACEGRNSORT1SHMT1 | |
| SCHEMBL8254029 | 0.93 | ACE2 (0.53) | ACE2ACEGRNSORT1SHMT1 | |
| SCHEMBL8430334 | 0.89 | ACE2 (0.41) | ACE2ACEGRNSORT1SHMT1 | |
| SCHEMBL5870350 | 0.88 | ACE2 (0.39) | ACE2ACEGRNSORT1ALDH1A1 | |
| SCHEMBL8255027 | 0.86 | HDAC1 (0.50) | ALDH1A1LMNAHDAC1HDAC6RAB9A | |
| SCHEMBL8249245 | 0.86 | HDAC1 (0.50) | ALDH1A1LMNAHDAC1HDAC6RAB9A | |
| SCHEMBL5870055 | 0.86 | HDAC1 (0.50) | ALDH1A1LMNAHDAC1HDAC6RAB9A | |
| SCHEMBL5869952 | 0.83 | ACE2 (0.48) | ACE2ACEGRNSORT1SHMT1 | |
| SCHEMBL5869959 | 0.83 | ACE2 (0.48) | ACE2ACEGRNSORT1SHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | ACE2 2/4885ACE 1/4885GRN 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.